The Latest Breaking News from AbbVie

AbbVie has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

AbbVie Inc. (NYSE:ABBV) announced Monday that it will acquire Gilgamesh Pharmaceuticals Inc.’s lead investigational candidate for moderate-to-severe major depressive disorder (MDD).

While daily stock price moves tend to dominate headlines, shifts in fundamental ranking scores can often tell a deeper story about a company's trajectory. This week, Benzinga's proprietary Growth, Value, Quality and Momentum data revealed major swings among household names, from electric vehicles to pharmaceuticals and financials.

AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean…

An easy way to avoid the merits in the latest high-stake health care litigation.

AbbVie Inc. (NYSE:ABBV), the manufacturer of Imbruvica, is at the center of a constitutional challenge to the federal government's new Drug Price Negotiation Program.

Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.

Sector by sector, U.S. dividend stocks have outperformed so far this year, with historically dividend-friendly industries surpassing those with a more growth-oriented focus.